Research Topics
| Gavin GiovannoniSummaryAffiliation: Queen Mary Country: UK Publications
| Collaborators
|
Detail Information
Publications
Multiple sclerosis: the environment and causationGavin Giovannoni
Institute of Cell and Molecular Science, Queen Mary University London, London, UK
Curr Opin Neurol 20:261-8. 2007..We review current thinking on the aetiology of multiple sclerosis, how genetic susceptibility interacts with environmental risk factors at the population level, multiple sclerosis-associated risk factors and contemporary causation theory...- Patients with clinically isolated syndromes suggestive of MS: does MRI allow earlier diagnosis?Gavin Giovannoni
Neurology 60:6-7. 2003 - Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practicesGavin Giovannoni
Neuroimmunology Unit, Neuroscience Centre, Institute of Cell and Molecular Science, Queen Mary s School of Medicine and Dentistry, Whitechapel, London
Rev Neurol Dis 4:184-93. 2007..In this review we compare current recommendations for the use of first-line DMTs, adverse events associated with MS therapies, and differences between the practices in North American and the European Union... - A placebo-controlled trial of oral cladribine for relapsing multiple sclerosisGavin Giovannoni
Queen Mary University London, the Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
N Engl J Med 362:416-26. 2010..Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis... - Individualizing treatment goals and interventions for people with MSGavin Giovannoni
Centre for Neuroscience and Trauma, Barts and the London School of Medicine and Dentistry, London, UK
Curr Opin Neurol 25:S20-7. 2012..These issues have increased in importance with the availability of new disease-modifying therapies and will continue to do so as more novel treatments are approved... - Promising emerging therapies for multiple sclerosisGavin Giovannoni
Neuroscience and Trauma Centre, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AN, UK
Neurol Clin 29:435-48. 2011..There is a large unmet need, with several promising new therapies in the pipeline. This article reviews the proposed mechanisms of action of the anticipated treatments, their efficacy, and risks associated with their use... - Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsG Giovannoni
Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
Mult Scler 15:219-28. 2009..c.) interferon-beta-1a has been developed (Rebif New Formulation, RNF), produced without fetal bovine serum and without human serum albumin as an excipient, with the aim of improving injection tolerability, and reducing immunogenicity... - Epstein-Barr Virus and MSG Giovannoni
Gavin Giovannoni Neuroscience and Trauma Centre, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK, Tel 44 20 7377 7472, Fax 44 20 7377 7300, E mail
Int MS J 17:44-9. 2011..Causation, however, is a complex science and more extensive and definitive data is required to convince the wider community that EBV is the pivotal factor in the complex causal pathway that ultimately leads to the development of MS... - Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisGavin Giovannoni
Queen Mary University London, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
Lancet Neurol 10:329-37. 2011.... - Fingolimod modulates microglial activation to augment markers of remyelinationSamuel J Jackson
Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
J Neuroinflammation 8:76. 2011..In addition, it is brain penetrant and has been shown to exert multiple effects on nervous system cells... - Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisGavin Giovannoni
Neuroimmunology Unit, Institute of Cell and Molecular Science, Queen Mary University London, London, United Kingdom
Clin Ther 29:1128-45. 2007..It was developed with the aim of maximizing the treatment benefit for patients with multiple sclerosis (MS) by improving injection tolerability and reducing the development of neutralizing antibodies (NAbs)... - Antineuronal antibodies in Parkinson's diseaseBart P C van de Warrenburg
Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom
Mov Disord 23:958-63. 2008..We conclude that ANAs do not play a role in the majority of patients with IPD, but might be relevant in the pathogenesis of IPD with atypical features... - Development of resistance to biologic therapies with reference to IFN-?Rachel A Farrell
Department of Neuroinflammation, UCL Institute of Neurology, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London E1 2AT, UK
Rheumatology (Oxford) 51:590-9. 2012.... - Antineuronal antibody status and phenotype analysis in Tourette's syndromeDavide Martino
Department of Neuroinflammation, Institute of Neurology, University College London, London, United Kingdom
Mov Disord 22:1424-9. 2007..14; P = 0.002; 95% confidence interval 0.04-0.49). ANeA status does not differentiate a specific phenotype of GTS... - Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitisSharmilee Gnanapavan
Department of Neuroimmunology, Institute of Neurology, London, UK
Autoimmunity 45:298-303. 2012..These data further support neurofilament levels as a good surrogate measure of neurodegeneration and their potential use as a surrogate endpoint in neuroprotective studies... - Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosisRachel A Farrell
Department of Neuroimmunology, Institute of Neurology, London, UK
Mult Scler 13:567-77. 2007.... - Multiple sclerosis cerebrospinal fluid biomarkersGavin Giovannoni
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK
Dis Markers 22:187-96. 2006..Bulk biomarkers of the neurodegenerative process such as glial fibrillary acidic protein (GFAP) and neurofilaments (NF) have advantages over intermittent inflammatory markers... - Vitamin D deficiency--do we follow our own advice?Ruth Dobson
Queen Mary University of London, Neuroimmunology Group, Blizard Institute, Barts and the London School of Medicine and Dentistry
Clin Med 11:521-3. 2011.... - Quantitative demonstration of intrathecal synthesis of high affinity immunoglobulin G in herpes simplex encephalitis using affinity-mediated immunoblottingMiles D Chapman
Department of Neuroimmunology, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
J Neuroimmunol 185:130-5. 2007..Digitisation of the blots enabled further analysis. We showed that the clones of antigen-specific IgG, which were produced intrathecally, were of higher relative affinity than polyclonal antigen-specific IgG... - Evidence for acute neurotoxicity after chemotherapyAxel Petzold
Department of Neuroimmunology, UCL Institute of Neurology, Queen Square, London, United Kingdom
Ann Neurol 68:806-15. 2010..Neurotoxicity adversely affects patients' quality of life. The objective of this study is to examine whether there is evidence of acute neurotoxicity... - More to come: humoral immune responses in MSRuth Dobson
Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London E1 2AT, UK
J Neuroimmunol 240:13-21. 2011..In this review we will discuss the potential role of B-cells in MS, how this influences our understanding of the disease, and potential therapeutic implications... - Immunopathogenesis and immunotherapeutic approaches in multiple sclerosisEe Tuan Lim
University College London, Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
Expert Rev Neurother 5:379-90. 2005..A number of new approaches likely to manipulate the immunopathogenesis of multiple sclerosis and which may ultimately allow for the development of more effective immunotherapy are also highlighted... - Management of secondary-progressive multiple sclerosisGavin Giovannoni
Department of Neuroinflammation, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
CNS Drugs 18:653-69. 2004..The aim of symptomatic therapies should not only be to reduce neurological impairments but also to decrease disability and handicap and to improve the emotional well-being and health-related quality of life of patients with SPMS... - Neural cell adhesion molecule--description of a CSF ELISA method and evidence of reduced levels in selected neurological disordersSharmilee Gnanapavan
Department of Neuroimmunology, Institute of Neurology, London, UK
J Neuroimmunol 225:118-22. 2010..Significant reductions were found between controls and multiple sclerosis, Alzheimer's disease and meningitis... - Role of the HLA system in the association between multiple sclerosis and infectious mononucleosisSreeram V Ramagopalan
Blizard Institute of Cell and Molecular Science, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, England, UK
Arch Neurol 68:469-72. 2011..To determine whether multiple sclerosis (MS) and infectious mononucleosis (IM) share common HLA associations... - The effect of gender in clinically isolated syndrome (CIS): a meta-analysisRuth Dobson
1Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
Mult Scler 18:600-4. 2012..32). The RR of females developing MS following CIS was 1.20 (95% CI 0.98-1.46) compared with males. Conclusions: These data imply that the gender bias seen in MS is caused by factors acting early in the disease process... - Current and future role of interferon beta in the therapy of multiple sclerosisRachel A Farrell
Institute of Neurology, University College London, London, United Kingdom
J Interferon Cytokine Res 30:715-26. 2010..We also review the efficacy of each drug, use of combination therapy strategies, and the potential role of the interferon beta preparations in the future... - Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitisSarah Al-Izki
Centre of Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK
Mult Scler 17:939-48. 2011..FTY720 has activity against lymphocytes but may also influence oligodendroglia and could therefore have the potential to influence progressive MS, by promoting remyelination... - Multiple sclerosis: risk factors, prodromes, and potential causal pathwaysSreeram V Ramagopalan
Blizard Institute of Cell and Molecular Science, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
Lancet Neurol 9:727-39. 2010.... - Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1aEe Tuan Lim
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK
J Negat Results Biomed 3:4. 2004..Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures... - No evidence for production of intrathecal immunoglobulin G against Acinetobacter or Pseudomonas in multiple sclerosisMiles D Chapman
Department of Neuroimmunology, Institute of Neurology, Queen Square, London, UK
Eur Neurol 53:27-31. 2005..other neurological diseases, and so conclude that A. calcoaceticus and P. aeruginosa are unlikely to be implicated in the pathogenesis of MS... - Emerging therapies in multiple sclerosisRachel Farrell
Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
Expert Opin Emerg Drugs 10:797-816. 2005..Many of the treatments discussed in this review are still at early stages of development, but provide exciting potential treatment options; others have proved disappointing in larger extended-phase studies... - The McDonald Criteria for Multiple Sclerosis: time for clarificationChristopher H Hawkes
Queen Mary University of London, Neuroscience and Trauma Centre, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
Mult Scler 16:566-75. 2010..There was uncertainty about how many multiple sclerosis categories were permitted and whether the terms 'possible' and 'probable' were allowable. Further clarification might allow the criteria to be applied more consistently... - Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodiesGavin Giovannoni
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK
Neurology 61:S13-7. 2003..Strategies used to prevent or reverse the development of NAbs with other biologic compounds, including improvements in the manufacturing process, immunosuppression, induction of tolerance, and deimmunization, will be reviewed... - Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosisSelina Davies
Department of Infectious Diseases and Transplantation Biology Group, MRC Clinical Sciences Center, Imperial College, Hammersmith Hospital, London, UK
J Neuropathol Exp Neurol 64:371-7. 2005..This may argue against a simple causal role of epitope spread in driving progression, as has been suggested in experimental allergic encephalomyelitis... - Autoaggressive immune-mediated movement disordersDavide Martino
Institute of Neurology, Department of Neuroimmunology, University College London, London, United Kingdom
Adv Neurol 96:320-35. 2005.... - PANDAS: overview of the hypothesisGavin Giovannoni
Department of Neuroinflammnation, Institute of Neurology, University College London, London, United Kingdom
Adv Neurol 99:159-65. 2006 - Surviving stiff-person syndrome: a case reportSharmilee Gnanapavan
Department of Neuroimmunology, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
J Neurol 258:1898-900. 2011..Here we describe the 15 year long management of a subject with SPS who has had a favourable outcome... - Cannabinoids inhibit neurodegeneration in models of multiple sclerosisGareth Pryce
Department of Neuroinflammation, Institute of Neurology, University College London, London, UK
Brain 126:2191-202. 2003..Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases... - Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UKRay Gani
Heron Evidence Development, Letchworth, UK
Pharmacoeconomics 26:617-27. 2008..These patients are those who experience higher relapse rates and faster disability progression than the general RRMS population... - Neutralising antibodies against interferon beta in multiple sclerosisGavin Giovannoni
Lancet 363:166-7; author reply 168-9. 2004 - Optimising MS disease-modifying therapies: antibodies in perspectiveGavin Giovannoni
Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
J Neurol 251:v30-v35. 2004.... - Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statementMark S Freedman
Department of Medicine Neurology, University of Ottawa, Multiple Sclerosis Research Clinic, The Ottawa Hospital, Ottawa, Ontario, Canada
Arch Neurol 62:865-70. 2005..These recommendations for establishing a standard for the evaluation of CSF in patients suspected of having MS should greatly complement the new criteria in ensuring that a correct diagnosis of MS is being made... - Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?Gavin Giovannoni
Neurology 65:6-8. 2005 - The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disordersGavin Giovannoni
Department of Neuroimmunology, Institute of Neurology, Queen Square, London WC1N 3BG, UK
J Neuroimmunol 180:29-32. 2006..We have extended this technique to individual clones and followed the maturation of clones during the course of herpes encephalitis. This has important implications for our understanding of the pathogenesis of multiple sclerosis... - Infectious causes of multiple sclerosisGavin Giovannoni
Department of Neuroinflammation, Institute of Neurology, University College London, UK
Lancet Neurol 5:887-94. 2006 - Neutralising antibodies to interferon beta in multiple sclerosis : expert panel reportHans P Hartung
Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
J Neurol 254:827-37. 2007.... - Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick
Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Ann Neurol 62:335-46. 2007..To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab... - The Rebif new formulation story: it's not trials and errorAmer Jaber
Merck Serono International SA, Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany
Drugs R D 8:335-48. 2007..Further assessment of RNF and other MS drugs is ongoing with the aim of enhancing the therapeutic options available for patients with MS... - Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosisJ Ludovic Croxford
Department of Neuroinflammation, Institute of Neurology, University College London, London WC1N 1PJ, United Kingdom
J Neuroimmunol 193:120-9. 2008..This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS... - Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosisRachel Farrell
J Int Med Res 36:204-8; author reply 208-10. 2008 - CSF analysis in suspected MS: do bands aid?Rogier Q Hintzen
Neurology 70:1059-60. 2008 - Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patientsRegina Lam
Neuro Immunology Laboratory, University of British Columbia, Vancouver, Canada
J Immunol Methods 336:113-8. 2008..8-29.3%, and the intra-assay coefficient of variation was between 6.3-15.2%. The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods... - The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up studyGerard Davies
Department of Neuroinflammation, Institute of Neurology, University College London
Neurology 60:1163-6. 2003..In the 18 subjects who either reverted to having normal CSF IEF or continued to exhibit only the monoclonal band, no cases of MS were encountered. Importantly, one of these had cerebral lymphoma...